Construction of a Fabry Disease Cardiomyocyte Model Overcoming Patient Sample Limitations via Base Editing and Successful Prime Editing

Background
Fabry disease is a rare metabolic disorder caused by defects in the alpha-galactosidase A (GLA) gene. A deficiency in the enzyme activity that breaks down globotriaosylceramide (Gb3) within lysosomes leads to abnormal accumulation of glycosphingolipids throughout the body. Extracellular matrix deposition in myocardial tissue is a fatal factor that leads to left ventricular hypertrophy, arrhythmias, and heart failure, resulting in premature death in patients. The question remains: where lies the solution to precisely replicate and treat these cardiac complications in vitro?
The problem is that the location of reported GLA mutations varies for every patient. Depending on the mutation site, the severity of enzyme deficiency and responsiveness to drug therapy differ significantly. Previously, human induced pluripotent stem cells (hiPSCs) created from patient somatic cells were mainly used to elucidate disease mechanisms. However, it was extremely difficult to secure sufficient patient samples with specific mutations. Another obstacle is the difficulty in distinguishing whether differences in drug response are due to specific mutations or individual genetic backgrounds. Therefore, there was an urgent need to establish an isogenic control model that could isolate and compare the effects of specific mutations within the same genetic background.
Key Findings
To overcome these limitations, researchers established a disease model by applying precision gene editing technology to normal hiPSCs. Introduction of two types of point mutations into the GLA gene of normal stem cells using adenine base editors (ABE) and cytosine base editors (CBE), respectively. As a result, they succeeded in constructing two types of Fabry disease hiPSC lines carrying only the target mutations, along with isogenic control cell lines, all sharing the same genetic background.
These established cell lines were differentiated into functional cardiomyocytes (CMs) to analyze pathological characteristics. The cardiomyocytes with mutations induced by base editing exhibited significantly reduced GLA enzyme activity and a sharp increase in intracellular Gb3 accumulation compared to the normal control, representing a typical cardiomyopathy phenotype. Could existing therapeutic drugs work effectively in this model? Upon administration of the pharmacological chaperone 1-deoxygalactonojirimycin (DGJ), a therapeutic response was confirmed, with a clear restoration of GLA enzyme activity in the defective cardiomyocytes.
Furthermore, the researchers demonstrated the possibility of gene therapy using the next-generation correction technology, prime editing (PE). The method involves delivering PE tools to Fabry disease hiPSCs to revert the mutation sequences back to normal sequences before differentiating them into CMs. The CMs subjected to the correction process restored GLA protein expression levels and enzyme activity to those of the normal control group, and intracellular Gb3 accumulation decreased to within normal ranges. This achievement demonstrates the ability to produce mutant cell lines and fully verify the efficacy of precision correction in vitro without the need for patient samples.
Significance and Outlook
This achievement is significant in that it shifts traditional rare disease research, which relied on patient biopsies, toward gene correction technology. It is expected to accelerate customized drug screening by enabling the rapid production of various GLA mutation libraries within a single genetic background. Existing enzyme replacement therapy (ERT) requires lifelong periodic intravenous injections and is limited by the formation of neutralizing antibodies and poor myocardial delivery. In contrast, PE-based correction offers the potential of a one-time therapeutic agent that fundamentally addresses the root cause of the disease.
Can success at the in vitro cell level lead directly to a cure in patients in vivo? The development of high-efficiency in vivo delivery systems capable of safely transporting correction complexes into myocardial tissue is identified as an essential prerequisite. A nonclinical evaluation should also follow to precisely verify off-target risks and elucidate long-term safety. Nevertheless, this precision platform based on isogenic cells is expected to establish itself as a standard research tool for predicting the efficacy and toxicity of drug candidates with high reliability before entering clinical trials.
PURPOSE: Fabry disease (FD) is a genetic disorder caused by loss-of-function mutations in the alpha-galactosidase A (GLA) gene. METHODS: Two point mutations were introduced into the GLA gene. RESULTS: FD phenotypes were confirmed in FD cardiomyocytes (CMs) by reduced GLA activity and increased Gb3 accumulation compared with isogenic controls. Treatment with the pharmacological chaperone 1-deoxygalactonojirimycin restored GLA enzyme activity in FD CMs. Additionally, CMs derived from hiPSCs corrected by prime editing exhibited GLA protein levels and enzyme activity comparable to those of the isogenic control, with a decrease in Gb3 accumulation. CONCLUSIONS: Our results demonstrate that base-edited isogenic hiPSC-CMs provide a personalized platform for evaluating therapeutic efficacy without patient-derived samples. Moreover, genetic correction of
This research can be immediately applied in the drug development field as a platform for patient-specific companion diagnostics and efficacy evaluation. When developing new chaperone therapies or substrate reduction therapies, it becomes possible to pre-screen drug responsiveness by mutation without using actual patient samples, thereby enabling the selection of the optimal target population. In the clinical trial stage, the success rate of clinical trials can be significantly increased by stratifying patient groups with specific genetic mutations that show high drug response rates. In the long term, expansion into the development of customized gene therapies that permanently correct genetic mutations in patients with severe cardiomyopathy is expected by combining prime editing technology with adeno-associated virus (AAV) or lipid nanoparticle (LNP) technologies targeting myocardial tissue.